Alcon Q2 Sales Climb 8% on New Product Launches; Core Margin and EPS Outlook Raised Despite $402M PowerVision Charge
ALC sits 25% above its 52-week low of $61.835.
Summary
Alcon reported Q2 2026 sales of $2.8 billion (+8% reported) and raised full-year core margin and EPS guidance, offset by a $402 million non-cash charge from discontinuing the PowerVision IOL programs.
Key Events · Earnings and Guidance · ALC
-
Q2 Sales Up 8% on New Products
Second-quarter 2026 sales reached $2.8 billion, up 8% reported and 7% constant currency, driven by recent launches including UNITY, PanOptix Pro, and TRYPTYR. Surgical grew 8% and Vision Care grew 8%.
-
Core EPS Beats, Guidance Raised
Core diluted EPS of $0.84 rose 11% vs. prior year. Management raised full-year 2026 guidance for core operating margin (now +90 to +190 bps) and core diluted EPS growth (now +12% to +15% constant currency).
-
$402M Non-Cash PowerVision Charge
Alcon recorded a $402 million pre-tax non-cash impairment charge after discontinuing the PowerVision IOL programs due to unacceptable patient outcomes in clinical studies. The charge has no cash impact and does not alter long-range financial objectives.
-
$538M Returned to Shareholders YTD
Year-to-date, Alcon returned $538 million to shareholders through $174 million in dividends and $364 million in share repurchases. A new $1.5 billion buyback program was authorized in May 2026, with $1.2 billion remaining.
Analysis · ALC · Industrial Applications And Services
A strong second quarter saw sales reach $2.8 billion, an 8% reported increase, fueled by new product launches including UNITY, PanOptix Pro, and TRYPTYR. Core operating margin expanded 150 basis points to 20.6%, and core diluted EPS of $0.84 beat the prior year by 11%. Reflecting confidence in the innovation pipeline, management raised full-year guidance for both core operating margin and core diluted EPS growth. The quarter did, however, include a $402 million pre-tax non-cash charge from discontinuing the PowerVision IOL programs after clinical data showed unacceptable patient outcomes — a setback that wipes out the carrying value of that acquired asset but does not impact cash or long-range financial objectives. Year-to-date, the company returned $538 million to shareholders through dividends and buybacks, with $1.2 billion remaining on its new $1.5 billion repurchase authorization. The combination of strong operational momentum and a one-time R&D write-down makes this a mixed but net positive update.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALC was trading at $77.30 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $36.8B. The 52-week trading range was $61.84 to $90.41. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.